fashion -WSS

fashion

author：leisure time 2025-09-06 02:16:20 - browse：58

Medical illustration of Streptococcus pneumoniae bacteria — A medical illustration of drug-resistant, Streptococcus pneumoniae bacteria. Antibiotic Resistance Coordination and Strategy Unit/CDC

Micronoma, a San Diego-based biotech startup, was founded on the idea that signatures from microbes that colonize tumors could lead to a blood test to detect cancer. The hypothesis was based on a high-profile Nature paper, published in 2020, that suggested these microbes are consistently found in tumors, and that they create such specific signatures they could be used to identify cancer types with nearly 100% accuracy.

But late Monday night, a team of researchers published a manuscript on the preprint site bioRxiv.com showing what they believe to be two “fatal errors” in the Nature paper’s analyses, invalidating not only the paper’s findings but possibly the scientific foundation for Micronoma, which has raised an estimated $17.5 million in funding from investors including SymBiosis Capital Management and the Seerave Foundation.

One allegation is that the Nature paper’s authors didn’t adequately filter out human DNA from their database of tumor samples, leading them to incorrectly classify millions of human sequences as bacterial. The other is that a separate error led the team’s algorithm to find false associations between specific microbial signatures and cancer types.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： To bolster infectious disease surveillance, genomics powerhouses team up

hotspot

leisure time

WSS

WuXi Biologics beefs up its lobbying operation

Novo Nordisk testing Wegovy against alcohol

Medicare bonuses could stop drug shortages under Senate plan

The White House hikes tariffs on plastic syringes made in China

What causes osteoarthritis? Researchers study link to brain protein

TikTok, Instagram influencers need more rules for drug ads

hotspot

fashion

focus

Drug repurposing or repositioning? The language matters

CVS is willing to dump 10% of its Medicare Advantage members

Psychedelics group wrestles with new pharma identity

To bolster infectious disease surveillance, genomics powerhouses team up

Drug repurposing or repositioning? The language matters

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

The cancer drug shortage isn’t new — and neither are the solutions

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Novavax promises a turnaround & Lilly roils the obesity market

WuXi Biologics beefs up its lobbying operation

explore

What causes osteoarthritis? Researchers study link to brain protein

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

There's an unseen cost to disruptive road

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Oak Street deal isn't the answer to health care's woes

Maisha Meds is a PBM, but don't call it that

hotspot

hotspot

leisure time

knowledge